This possibility is supported by evidence from syngeneic ovarian tumors, where combining chemotherapy with a CSF1R inhibitor (AZD7507) resulted in a decline in antitumor efficacy compared to chemotherapy alone (53). Here, CSF1R is linked to ovarian neoplasm.